Loading...
Macitentan for the treatment of pulmonary arterial hypertension
Macitentan is the most recently approved dual endothelin-receptor antagonist (ERA) for the treatment of symptomatic pulmonary arterial hypertension. Compared to other available ERAs, it demonstrates superior receptor-binding properties, with consequently improved tissue penetration, and a longer dur...
Na minha lista:
| Udgivet i: | Vasc Health Risk Manag |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2014
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4251661/ https://ncbi.nlm.nih.gov/pubmed/25473292 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/VHRM.S33904 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|